Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, June 12, 2014, 85 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $100.00 to $24,196,620.00.

Highlighted Stocks Traded by Insiders:

Furiex Pharmaceuticals (FURX) - FREE Research Report

Covington Paul S, who is Senior VP-Clinical Operations at Furiex Pharmaceuticals, sold 2,872 shares at $104.63 on June 12, 2014. Following this transaction, the Senior VP-Clinical Operations owned 25,751 shares meaning that the stake was reduced by 10.03% with the 2,872-share transaction.

McIntyre Gail Frances, who is Senior Vice President-Research at Furiex Pharmaceuticals, sold 1,746 shares at $104.58 on June 12, 2014. Following this transaction, the Senior Vice President-Research owned 28,122 shares meaning that the stake was reduced by 5.85% with the 1,746-share transaction.

Patel Sailash, who is Chief Financial Officer at Furiex Pharmaceuticals, sold 1,504 shares at $104.68 on June 12, 2014. Following this transaction, the Chief Financial Officer owned 26,444 shares meaning that the stake was reduced by 5.38% with the 1,504-share transaction.

The shares most recently traded at $104.25, down $0.43, or 0.41% since the insider transaction. Historical insider transactions for Furiex Pharmaceuticals go as follows:

  • 24-Week # shares sold: 385

The average volume for Furiex Pharmaceuticals has been 315,000 shares per day over the past 30 days. Furiex Pharmaceuticals has a market cap of $1.1 billion and is part of the health care sector and drugs industry. Shares are up 149.06% year-to-date as of the close of trading on Thursday.

Furiex Pharmaceuticals, Inc. operates as a drug development company that is involved in compound development and collaboration activities primarily in the United States. Currently, there are 2 analysts who rate Furiex Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FURX - FREE

TheStreet Quant Ratings rates Furiex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk. Get the full Furiex Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

EastGroup Properties (EGP) - FREE Research Report

Bailey H C Jr, who is Director at EastGroup Properties, sold 1,745 shares at $64.42 on June 12, 2014. Following this transaction, the Director owned 7,000 shares meaning that the stake was reduced by 19.95% with the 1,745-share transaction.

The shares most recently traded at $63.71, down $0.71, or 1.12% since the insider transaction. Historical insider transactions for EastGroup Properties go as follows:

  • 4-Week # shares sold: 5,220
  • 12-Week # shares sold: 5,220
  • 24-Week # shares sold: 22,489

The average volume for EastGroup Properties has been 169,800 shares per day over the past 30 days. EastGroup Properties has a market cap of $2.0 billion and is part of the financial sector and real estate industry. Shares are up 10.41% year-to-date as of the close of trading on Thursday.

EastGroup Properties, Inc., a real estate investment trust (REIT), focuses on the development, acquisition, and operation of industrial properties in the United States. The stock currently has a dividend yield of 3.34%. The company has a P/E ratio of 59.9. Currently, there are 4 analysts who rate EastGroup Properties a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EGP - FREE

TheStreet Quant Ratings rates EastGroup Properties as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, revenue growth, increase in stock price during the past year and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full EastGroup Properties Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Fleetcor Technologies (FLT) - FREE Research Report

Downs Timothy, who is Pres, Corp Lodging Consultants at Fleetcor Technologies, sold 3,700 shares at $130.12 on June 12, 2014. Following this transaction, the Pres, Corp Lodging Consultants owned 17,756 shares meaning that the stake was reduced by 17.24% with the 3,700-share transaction.

The shares most recently traded at $132.22, up $2.10, or 1.59% since the insider transaction. Historical insider transactions for Fleetcor Technologies go as follows:

  • 4-Week # shares bought: 5,000
  • 4-Week # shares sold: 600
  • 12-Week # shares bought: 5,000
  • 12-Week # shares sold: 11,600
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 240,072

The average volume for Fleetcor Technologies has been 780,800 shares per day over the past 30 days. Fleetcor Technologies has a market cap of $10.9 billion and is part of the services sector and diversified services industry. Shares are up 12.46% year-to-date as of the close of trading on Thursday.

FleetCor Technologies, Inc. provides fuel cards and workforce payment products and services in North America, Latin America, Europe, Australia, and New Zealand. The company has a P/E ratio of 37.8. Currently, there are 3 analysts who rate Fleetcor Technologies a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FLT - FREE

TheStreet Quant Ratings rates Fleetcor Technologies as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share, compelling growth in net income, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Fleetcor Technologies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null